
  
    
      
        Background_NNP
        A_DT near-universal_JJ feature_NN of_IN cell_NN signaling_VBG 
        via_IN seven_CD transmembrane_NN ,_, G_NNP
        protein-coupled_JJ receptors_NNS is_VBZ attenuation_NN of_IN a_DT cellular_JJ
        response_NN upon_IN prolonged_JJ exposure_NN to_TO an_DT extracellular_NN
        stimulus_NN [_NN 1_CD ]_NN ._. This_DT desensitization_NN process_NN is_VBZ
        well-established_JJ for_IN GnRH-stimulated_NNP LH_NNP secretion_NN from_IN
        pituitary_JJ gonadotropes_NNS [_NN 2_CD 3_CD ]_NN ,_, and_CC occurs_VBZ after_IN about_IN 6_CD h_NN
        of_IN continued_JJ exposure_NN to_TO GnRH_NNP in_IN rats_NNS [_NN 3_CD ]_NN ;_: removal_NN of_IN
        GnRH_NNP permits_VBZ recovery_NN from_IN the_DT profound_JJ suppression_NN of_IN LH_NNP
        secretion_NN ,_, albeit_IN rather_RB slowly_RB (_( 2_CD -_: 4_CD days_NNS ;_: 4_LS )_) ._. The_DT
        molecular_JJ mechanisms_NNS involved_VBN in_IN GnRH-induced_NNP
        desensitization_NN are_VBP poorly_RB understood_VBN ,_, but_CC they_PRP do_VBP not_RB
        appear_VB to_TO be_VB due_JJ to_TO alterations_NNS in_IN GnRH_NNP receptor_NN expression_NN
        [_NN 5_CD 6_CD ]_NN or_CC to_TO changes_NNS in_IN LH_NNP concentrations_NNS in_IN the_DT pituitary_JJ
        gland_NN [_NN 7_CD 8_CD ]_NN ._.
        Earlier_RBR ,_, we_PRP presented_VBD evidence_NN that_IN a_DT regulator_NN of_IN G_NNP
        protein_NN signaling_VBG ,_, RGS_NNP 3_CD ,_, might_MD participate_VB in_IN the_DT
        regulation_NN of_IN GnRH_NNP receptor_NN signaling_VBG [_NN 9_CD ]_NN ._. The_DT mechanism_NN
        of_IN RGS_NNP action_NN is_VBZ antagonism_NN of_IN the_DT Gα_NNP protein_NN either_CC by_IN
        accelerating_VBG its_PRP$ hydrolysis_NNS of_IN GTP_NNP ,_, thereby_RB prematurely_RB
        terminating_VBG signaling_VBG due_JJ to_TO reassociation_NN of_IN the_DT Gα_NNP and_CC
        Gβγ_NNP complexes_NNS [_NN 10_CD ]_NN ,_, or_CC by_IN antagonizing_VBG interaction_NN of_IN
        the_DT Gα_NNP protein_NN with_IN its_PRP$ effector_NN such_JJ as_IN phospholipase_NN Cβ_NNP [_NN
        11_CD 12_CD ]_NN ._. A_DT large_JJ number_NN of_IN RGS_NNP genes_NNS have_VBP been_VBN identified_VBN
        in_IN mammals_NNS based_VBN on_IN the_DT presence_NN of_IN a_DT 120_CD amino_JJ acid_NN core_NN
        domain_NN [_NN 13_CD 14_CD 15_CD 16_CD ]_NN ._. RGS_NNP proteins_NNS have_VBP been_VBN described_VBN
        that_DT interact_NN with_IN the_DT G_NNP 
        i_NNP α_NN and_CC G_NNP 
        qα_NN members_NNS of_IN the_DT G_NNP protein_NN family_NN [_NN 17_CD
        18_CD 19_CD 20_CD 21_CD ]_NN ._.
        Previously_RB ,_, we_PRP showed_VBD that_IN RSG_NNP 3_CD was_VBD expressed_VBN
        endogenously_RB in_IN rat_NN pituitary_JJ cells_NNS and_CC ,_, when_WRB
        experimentally_RB co-expressed_JJ together_RB with_IN GnRH_NNP receptors_NNS in_IN
        a_DT heterologous_JJ cell_NN line_NN (_( COS_NNP 1_LS )_) ,_, it_PRP suppressed_VBD
        GnRH-stimulated_NNP inositol_NN trisphosphate_NN production_NN [_NN 9_CD ]_NN ._.
        Here_RB ,_, those_DT studies_NNS have_VBP been_VBN extended_VBN to_TO include_VB
        GnRH-stimulated_NNP LH_NNP secretion_NN using_VBG adenovirus-mediated_JJ gene_NN
        transfer_NN of_IN RGS_NNP 3_CD complementary_JJ DNA_NNP into_IN normal_JJ rat_NN
        pituitary_JJ gonadotropes_NNS ._. RGS_NNP 3_CD was_VBD found_VBN to_TO profoundly_RB
        inhibit_VB GnRH-stimulated_NNP LH_NNP secretion_NN and_CC 3_CD H-_NNP inositol_NN
        phosphate_NN accumulation_NN ._. However_RB ,_, a_DT calcium_NN ionophore_NN
        stimulated_VBN LH_NNP secretion_NN in_IN RGS_NNP 3_CD -_: expressing_VBG gonadotropes_NNS ,_,
        confirming_VBG a_DT specific_JJ site_NN of_IN action_NN occurring_VBG at_IN
        phospholipase_NN Cβ_NNP or_CC earlier_RBR in_IN the_DT signal_NN transduction_NN
        pathway_NN ._.
      
      
        Results_NNS
        The_DT initial_JJ experiments_NNS were_VBD performed_VBN to_TO confirm_VB our_PRP$
        earlier_RBR finding_VBG that_IN RGS_NNP 3_CD suppressed_VBN GnRH-stimulated_NNP IP_NNP 
        3_CD production_NN in_IN COS-_NNP 1_CD cells_NNS [_NN 9_CD ]_NN and_CC to_TO
        test_VB a_DT truncated_JJ form_NN of_IN RGS_NNP 3_CD ,_, RGS_NNP 3_CD T_NN (_( RGS_NNP 3_CD 314_CD -_: 519_CD )_) [_NN 24_CD ]_NN
        for_IN suppressive_JJ activity_NN in_IN the_DT same_JJ assay_NN (_( Fig_NNP ._. 1_LS )_) ._. cDNAs_NNS
        representing_VBG the_DT GnRH_NNP receptor_NN and_CC RGS_NNP 3_CD or_CC RGS_NNP 3_CD T_NN were_VBD
        co-transfected_JJ into_IN COS-_NNP 1_CD cells_NNS for_IN GnRH-A_NNP treatment_NN 72_CD h_NN
        later_RB ;_: intracellular_NN IP_NNP 
        3_CD concentrations_NNS were_VBD measured_VBN at_IN 0_CD ,_, 10_CD ,_,
        20_CD ,_, and_CC 30_CD sec_NN after_IN addition_NN of_IN 10_CD -_: 7_CD M_NNP GnRH-A_NNP (_( Fig_NNP ._. 1_LS )_) ._. As_IN
        expected_VBN ,_, RGS_NNP 3_CD exerted_VBN a_DT profound_JJ suppression_NN of_IN IP_NNP 
        3_CD production_NN at_IN each_DT of_IN the_DT time_NN points_NNS
        during_IN the_DT 30_CD sec_NN after_IN agonist_NN treatment_NN (_( p_NN <_NN 0_CD ._. 05_CD )_)
        (_( Fig_NNP ._. 1_LS )_) ._. RGS_NNP 3_CD T_NN is_VBZ comprised_VBN primarily_RB by_IN the_DT consensus_NN RGS_NNP
        domain_NN and_CC was_VBD originally_RB reported_VBN to_TO decrease_VB the_DT growth_NN
        rate_NN of_IN yeast_NN and_CC to_TO inhibit_VB IL-_NNP 8_CD receptor_NN mediated_JJ
        activation_NN of_IN MAP_NNP kinase_NN by_IN a_DT factor_NN of_IN 3_CD -_: 10_CD fold_VB as_IN
        compared_VBN to_TO RGS_NNP 3_CD [_NN 24_CD ]_NN and_CC was_VBD subsequently_RB reported_VBN to_TO be_VB
        a_DT normally_RB expressed_VBN variant_NN of_IN RGS_NNP 3_CD [_NN 37_CD ]_NN ._. Therefore_RB ,_, we_PRP
        compared_VBD it_PRP to_TO RGS_NNP 3_CD for_IN attenuation_NN of_IN GnRH-stimulated_NNP IP_NNP 
        3_CD production_NN in_IN COS-_NNP 1_CD cells_NNS (_( Fig_NNP ._. 1_LS )_) ._. As_IN
        reported_VBN by_IN others_NNS [_NN 24_CD 37_CD ]_NN ,_, we_PRP found_VBD that_IN RGS_NNP 3_CD T_NN was_VBD more_RBR
        potent_JJ than_IN RGS_NNP 3_CD (_( p_NN <_NN 0_CD ._. 05_CD )_) (_( Fig_NNP ._. 1_LS )_) ._. Identification_NNP of_IN
        a_DT C-_NNP terminal_NN 205_CD amino_JJ acid_NN variant_NN of_IN RGS_NNP 3_CD that_WDT has_VBZ equal_JJ
        or_CC greater_JJR potency_NN than_IN the_DT full-length_JJ 519_CD amino_JJ acid_NN RGS_NNP 3_CD
        will_MD facilitate_VB the_DT identification_NN of_IN RGS_NNP 3_CD functional_JJ
        protein_NN domains_NNS that_WDT are_VBP important_JJ for_IN its_PRP$ activity_NN ._.
        The_DT family_NN of_IN RGS_NNP proteins_NNS are_VBP established_VBN to_TO interact_NN
        with_IN various_JJ Gα-protein_NNP subunits_NNS ,_, thereby_RB antagonizing_VBG
        their_PRP$ activities_NNS [_NN 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD 24_CD ]_NN ._. Indeed_RB ,_, we_PRP
        previously_RB reported_VBD that_IN RGS_NNP 3_CD bound_VBN Gqα_NNP [_NN 9_CD ]_NN ,_, the_DT G_NNP
        protein_NN subunit_NN that_IN mediates_NNS GnRH_NNP receptor_NN signaling_VBG [_NN 38_CD
        ]_NN ._. Here_RB ,_, we_PRP have_VBP extended_VBN those_DT binding_JJ studies_NNS to_TO include_VB
        other_JJ Gα_NNP proteins_NNS (_( Fig_NNP ._. 2_LS )_) ._. An_DT RGS_NNP 3_CD -_: GST_NNP fusion_NN protein_NN was_VBD
        incubated_JJ with_IN an_DT 35_CD S-M_NNP et-_NN Gα-protein_NNP ,_, and_CC the_DT amount_NN of_IN
        labeled_VBN Gα-protein_NNP was_VBD determined_VBN using_VBG glutathione-coupled_JJ
        beads_NNS to_TO "_'' pull_VB down_RB "_'' the_DT RGS_NNP 3_CD -_: GST_NNP /_NN 35_CD S-G_NNP α-protein_JJ complex_NN
        that_WDT was_VBD then_RB separated_JJ and_CC quantified_VBN by_IN SDS_NNP /_NN PAGE_NNP (_( Fig_NNP ._.
        2_LS )_) ._. More_JJR Gqα_NNP was_VBD bound_VBN by_IN RGS_NNP 3_CD than_IN any_DT other_JJ protein_NN ,_,
        although_IN its_PRP$ binding_JJ was_VBD not_RB significantly_RB different_JJ from_IN
        that_DT of_IN Gzα_NNP and_CC Giα_NNP (_( p_NN >_NN 0_CD ._. 05_CD )_) ._. Significant_JJ (_( p_NN <_NN
        0_CD ._. 05_CD )_) amounts_NNS of_IN Gi_NNP 2_CD α_NN ,_, Gi_NNP 1_CD α_NN ,_, Goα_NNP ,_, and_CC Gsα_NNP also_RB were_VBD bound_VBN
        but_CC were_VBD not_RB as_RB high_JJ as_IN Gqα_NNP ,_, Gzα_NNP ,_, and_CC Gi_NNP 3_CD α_NN ._. These_DT results_NNS
        confirm_VBP our_PRP$ previous_JJ findings_NNS that_IN RGS_NNP 3_CD interacts_NNS with_IN Gqα_NNP
        but_CC also_RB show_VB that_IN it_PRP has_VBZ significant_JJ interaction_NN with_IN all_DT
        other_JJ Gα-proteins_NNP studied_VBD ._.
        The_DT findings_NNS of_IN the_DT current_NN ,_, and_CC an_DT earlier_JJR study_NN [_NN 9_CD ]_NN
        ,_, demonstrate_VB clearly_RB that_IN RGS_NNP 3_CD suppresses_NNS GnRH_NNP receptor_NN
        signaling_VBG in_IN a_DT heterologous_JJ cell_NN system_NN ._. Because_IN of_IN the_DT
        evidence_NN that_IN the_DT signal_NN transduction_NN pathway_NN for_IN GnRH_NNP in_IN
        gonadotropes_NNS involves_VBZ the_DT GnRH_NNP receptor_NN ,_, Gqα_NNP ,_, phospholipase_NN
        Cβ_NNP ,_, and_CC cellular_JJ IP_NNP 
        3_CD release_NN [_NN 39_CD 40_CD ]_NN ,_, we_PRP determined_VBD the_DT
        effect_NN of_IN RGS_NNP 3_CD on_IN GnRH-stimulated_NNP LH_NNP secretion_NN using_VBG
        adenoviral-mediated_JJ gene_NN transfer_NN in_IN rat_NN pituitary_JJ cells_NNS
        (_( Fig_NNP ._. 3_LS )_) ._. In_IN these_DT experiments_NNS ,_, we_PRP performed_VBD a_DT
        dose-response_JJ test_NN that_WDT included_VBD three_CD experimental_JJ groups_NNS :_:
        uninfected_JJ ,_, adeno-β_JJ galactosidase_NN ,_, and_CC adeno-_NN RGS_NNP 3_CD infected_JJ ._.
        Adeno-βgal_NNP infection_NN was_VBD used_VBN for_IN determination_NN of_IN the_DT
        fraction_NN of_IN cells_NNS infected_VBN at_IN each_DT dose_NN of_IN virus_NN (_( Fig_NNP ._. 3_LS ,_,
        top_JJ panel_NN )_) and_CC as_IN a_DT control_NN for_IN the_DT effects_NNS of_IN adeno-_NN RGS_NNP 3_CD
        on_IN GnRH-stimulated_NNP LH_NNP secretion_NN (_( Fig_NNP ._. 3_LS ,_, middle_JJ panel_NN )_) ._.
        Cell_NNP viability_NN ,_, measured_VBN as_IN trypan_NN blue_JJ exclusion_NN ,_, varied_VBD
        from_IN 98_CD ._. 5_LS -_: 100_CD ._. 0_CD %_NN (_( Fig_NNP ._. 3_LS ,_, top_JJ panel_NN )_) ._. The_DT fraction_NN of_IN cells_NNS
        infected_VBN by_IN the_DT adenovirus_JJ depended_VBD on_IN viral_JJ dose_NN (_( 0_CD -_: 5_CD ._. 0_CD
        M_NNP ._. O_NNP ._. I_PRP ._. ;_: 1_CD M_NNP ._. O_NNP ._. I_PRP ._. =_SYM 1_CD viral_JJ particle_NN /_NN pituitary_JJ cell_NN )_) and_CC
        ranged_VBD from_IN about_IN 2_CD %_NN (_( no_DT adenovirus_JJ )_) to_TO 99_CD ._. 5_LS %_NN (_( 5_CD ._. 0_CD M_NNP ._. O_NNP ._. I_PRP ._. )_) ._.
        Adeno-βgal_NNP had_VBD no_DT effect_NN on_IN LH_NNP secretion_NN at_IN any_DT dose_NN
        compared_VBN to_TO the_DT uninfected_JJ group_NN (_( Fig_NNP ._. 3_LS ,_, middle_JJ panel_NN )_) ._. In_IN
        contrast_NN ,_, an_DT inverse_NN dose-related_JJ effect_NN was_VBD observed_VBN
        between_IN adeno-_NN RGS_NNP 3_CD and_CC GnRH-stimulated_NNP LH_NNP secretion_NN (_( Fig_NNP ._.
        3_LS ,_, bottom_JJ panel_NN )_) ._. RGS_NNP 3_CD 0_CD ._. 2_CD M_NNP ._. O_NNP ._. I_PRP ._. was_VBD the_DT lowest_JJS dose_NN to_TO
        inhibit_VB LH_NNP secretion_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) ,_, and_CC 2_CD ._. 0_CD and_CC 5_CD ._. 0_CD M_NNP ._. O_NNP ._. I_PRP ._.
        exerted_VBN near_IN complete_JJ inhibition_NN of_IN LH_NNP secretion_NN ;_: i_NNP ._. e_SYM ._. LH_NNP
        concentrations_NNS in_IN these_DT two_CD latter_JJ GnRH-treated_NNP groups_NNS did_VBD
        not_RB differ_VB from_IN their_PRP$ cohort_NN controls_NNS (_( p_NN >_NN 0_CD ._. 05_CD )_) ._.
        The_DT profound_JJ inhibition_NN of_IN GnRH-stimulated_NNP LH_NNP secretion_NN
        observed_VBD in_IN Fig_NNP ._. 3_LS required_VBN verification_NN that_IN RGS_NNP 3_CD
        expression_NN was_VBD induced_VBN by_IN adeno-_NN RGS_NNP 3_CD infection_NN ._. To_TO address_VB
        this_DT issue_NN ,_, we_PRP performed_VBD RGS_NNP 3_CD immunoblots_NNS (_( Fig_NNP ._. 4_LS )_) which_WDT
        showed_VBD an_DT increase_NN in_IN RGS_NNP 3_CD protein_NN expression_NN in_IN adeno-_NN RGS_NNP 3_CD
        (_( 5_CD ._. 0_CD M_NNP ._. O_NNP ._. I_PRP ._. )_) infected_JJ pituitary_JJ cells_NNS as_IN compared_VBN to_TO low_JJ to_TO
        negligible_JJ levels_NNS of_IN protein_NN in_IN the_DT uninfected_JJ and_CC
        adeno-βgal_JJ infected_JJ groups_NNS ._.
        As_IN evidenced_VBN earlier_RBR ,_, the_DT molecular_JJ locus_JJ of_IN RGS_NNP protein_NN
        action_NN is_VBZ thought_VBN to_TO be_VB the_DT G_NNP protein_NN α_NN subunit_NN ,_,
        specifically_RB Gqα_NNP in_IN the_DT case_NN of_IN GnRH_NNP receptor_NN activation_NN ._.
        The_DT results_NNS shown_VBN in_IN Fig_NNP ._. 5_LS are_VBP consistent_JJ with_IN this_DT
        conclusion_NN :_: adeno-_NN RGS_NNP 3_CD infection_NN of_IN rat_NN pituitary_JJ cells_NNS
        profoundly_RB suppressed_VBN GnRH-stimulated_NNP 3_CD H-_NNP inositol_NN phosphate_NN
        accumulation_NN ._. These_DT results_NNS are_VBP compatible_JJ with_IN a_DT molecular_JJ
        site_NN of_IN action_NN for_IN RGS_NNP 3_CD being_VBG at_IN phospholipase_NN C_NNP or_CC earlier_RBR
        in_IN the_DT signal_NN transduction_NN pathway_NN ._.
        Another_DT experiment_NN conducted_VBN to_TO test_VB the_DT specificity_NN and_CC
        molecular_JJ locus_JJ of_IN RGS_NNP 3_CD action_NN in_IN inhibiting_VBG
        GnRH-stimulated_NNP LH_NNP secretion_NN was_VBD treatment_NN of_IN adeno-_NN RGS_NNP 3_CD
        infected_VBN cells_NNS with_IN an_DT agent_NN that_IN increases_NNS intracellular_NN
        calcium_NN (_( Fig_NNP ._. 6_CD )_) ._. Calcium_NNP is_VBZ an_DT established_VBN stimulator_NN of_IN
        LH_NNP secretion_NN that_WDT is_VBZ thought_VBN to_TO act_VB at_IN sites_NNS downstream_JJ of_IN
        phospholipase_NN C_NNP [_NN 39_CD 40_CD ]_NN ._. Therefore_RB ,_, adeno-_NN RGS_NNP 3_CD infected_JJ
        pituitary_JJ cells_NNS were_VBD treated_VBN with_IN a_DT calcium_NN ionophore_NN
        (_( A_DT 23187_CD )_) ._. Adeno-_NNP RSG_NNP 3_CD inhibited_VBD LH_NNP secretion_NN in_IN the_DT
        GnRH-treated_NNP control_NN group_NN as_IN expected_VBN (_( Fig_NNP ._. 6_CD )_) ._. However_RB ,_,
        the_DT calcium_NN ionphore_NN stimulated_VBN LH_NNP secretion_NN in_IN
        RGS_NNP 3_CD -_: expressing_VBG gonadotropes_NNS (_( Fig_NNP ._. 6_CD )_) ,_, an_DT effect_NN that_WDT would_MD
        be_VB expected_VBN if_IN the_DT RGS_NNP 3_CD inhibition_NN was_VBD exerted_VBN at_IN the_DT level_NN
        of_IN the_DT Gqα_NNP protein_NN ._.
        In_IN two_CD final_JJ control_NN studies_NNS ,_, we_PRP investigated_VBD the_DT effect_NN
        of_IN adeno-_NN RGS_NNP 3_CD on_IN LH_NNP concentrations_NNS in_IN pituitary_JJ cells_NNS and_CC
        on_IN GnRH_NNP receptor_NN binding_JJ (_( Fig_NNP ._. 7_CD )_) ._. In_IN neither_DT case_NN did_VBD RGS_NNP 3_CD
        affect_VB these_DT parameters_NNS of_IN gonadotrope_NN function_NN (_( p_NN >_NN
        0_CD ._. 05_CD )_) ._.
      
      
        Discussion_NNP
        The_DT quantity_NN of_IN LH_NNP secreted_JJ by_IN the_DT anterior_NN pituitary_JJ
        gland_NN is_VBZ the_DT outcome_NN of_IN an_DT interaction_NN between_IN the_DT amount_NN
        of_IN hypothalamic_JJ GnRH_NNP secretion_NN and_CC the_DT level_NN of_IN gonadotrope_NN
        responsiveness_NNS to_TO GnRH_NNP [_NN 7_CD ]_NN ._. Quantitatively_NNP ,_, gonadotrope_NN
        responsiveness_NNS is_VBZ more_RBR important_JJ than_IN the_DT level_NN of_IN GnRH_NNP
        secretion_NN ;_: for_IN example_NN ,_, during_IN the_DT estrogen-stimulated_JJ
        preovulatory_NN surge_NN of_IN LH_NNP secretion_NN in_IN the_DT rat_NN there_EX is_VBZ a_DT
        5_CD -_: fold_VB increase_NN in_IN GnRH_NNP secretion_NN but_CC a_DT 50_CD -_: fold_VB increase_NN in_IN
        LH_NNP secretion_NN [_NN 7_CD ]_NN ._. Moreover_RB ,_, a_DT quantity_NN of_IN GnRH_NNP that_WDT will_MD
        evoke_VBP a_DT normal_JJ preovulatory_NN LH_NNP surge_NN during_IN the_DT period_NN
        preceding_VBG ovulation_NN will_MD induce_VB only_RB a_DT small_JJ increase_NN in_IN LH_NNP
        secretion_NN at_IN other_JJ stages_NNS of_IN the_DT estrous_JJ cycle_NN [_NN 7_CD ]_NN ._.
        Similarly_RB ,_, termination_NN of_IN the_DT preovulatory_NN LH_NNP surge_NN appears_VBZ
        to_TO be_VB due_JJ to_TO desensitization_NN of_IN the_DT gonadotrope_NN to_TO GnRH_NNP
        action_NN ;_: in_IN the_DT sheep_NN ,_, a_DT decrease_NN in_IN LH_NNP secretion_NN precedes_VBZ
        the_DT decrease_NN in_IN GnRH_NNP secretion_NN [_NN 41_CD ]_NN ,_, whereas_IN in_IN the_DT rat_NN ,_,
        although_IN the_DT decrease_NN in_IN GnRH_NNP and_CC LH_NNP secretion_NN are_VBP
        co-incident_JJ [_NN 7_CD ]_NN ,_, there_EX is_VBZ evidence_NN that_IN the_DT gonadotrope_NN
        is_VBZ already_RB desensitized_JJ to_TO GnRH_NNP [_NN 42_CD 43_CD ]_NN ._.
        The_DT mechanisms_NNS that_WDT alter_VBP gonadotrope_NN responsiveness_NNS to_TO
        GnRH_NNP are_VBP unknown_JJ but_CC they_PRP do_VBP not_RB appear_VB to_TO be_VB due_JJ to_TO GnRH_NNP
        receptor_NN number_NN or_CC LH_NNP stores_NNS in_IN the_DT pituitary_JJ gland_NN [_NN 5_CD 6_CD 7_CD
        8_CD ]_NN ._. However_RB ,_, the_DT fraction_NN of_IN LH_NNP that_WDT is_VBZ released_VBN by_IN a_DT
        maximal_NN dose_NN of_IN GnRH_NNP does_VBZ vary_VB positively_RB with_IN gonadotrope_NN
        responsiveness_NNS [_NN 7_CD ]_NN ,_, and_CC elucidation_NN of_IN the_DT mechanisms_NNS
        altering_VBG the_DT fraction_NN of_IN releasable_JJ LH_NNP is_VBZ likely_JJ to_TO
        illuminate_VB mechanisms_NNS of_IN gonadotrope_NN responsiveness_NNS to_TO GnRH_NNP
        [_NN 44_CD ]_NN ._.
        Two_CD molecular_JJ loci_NN recently_RB have_VBP been_VBN implicated_VBN as_IN
        potential_JJ modulators_NNS of_IN GnRH_NNP receptor_NN signaling_VBG :_: one_CD is_VBZ the_DT
        receptor_NN itself_PRP [_NN 23_CD ]_NN ,_, and_CC the_DT other_JJ is_VBZ the_DT G_NNP protein_NN
        that_IN transduces_NNS the_DT signal_NN generated_VBN by_IN binding_VBG of_IN the_DT
        receptor_NN to_TO its_PRP$ agonist_NN [_NN 9_CD ]_NN ._. With_IN respect_NN to_TO the_DT former_JJ
        locus_JJ ,_, G_NNP protein_NN coupled_VBN receptor_NN kinases_NNS (_( GRKs_NNP )_) act_NN in_IN an_DT
        agonist-specific_JJ manner_NN to_TO phosphorylate_NN intracellular_NN
        regions_NNS of_IN the_DT receptor_NN thus_RB permitting_VBG β_NN arrestin_NN binding_JJ
        that_IN sterically_RB inhibits_NNS G_NNP protein_NN association_NN with_IN the_DT
        receptor_NN [_NN 1_CD 45_CD ]_NN ._. We_PRP have_VBP reported_VBN previously_RB that_IN
        experimental_JJ expression_NN of_IN GRKs_NNP in_IN GnRH_NNP receptor-expressing_JJ
        heterologous_JJ cells_NNS (_( COS-_NNP 1_LS )_) suppressed_VBN GnRH-stimulated_NNP IP_NNP 
        3_CD production_NN ,_, and_CC that_IN co-expression_JJ of_IN
        GRK_NNP 2_CD and_CC β-arrestin_JJ 2_CD suppressed_VBN GnRH_NNP receptor_NN signaling_VBG
        more_JJR than_IN that_DT of_IN either_DT alone_RB [_NN 23_CD ]_NN ._. Stronger_JJR evidence_NN
        that_IN the_DT GRK_NNP /_NN β_NN arrestin_NN paradigm_NN may_MD play_VB a_DT role_NN in_IN
        regulating_VBG GnRH_NNP receptor_NN signaling_VBG is_VBZ our_PRP$ recent_JJ finding_NN
        that_IN adenovirus-mediated_JJ gene_NN transfer_NN of_IN GRK_NNP 2_CD into_IN normal_JJ
        pituitary_JJ gonadotropes_NNS suppressed_VBD GnRH-stimulated_NNP LH_NNP
        secretion_NN and_CC IP_NNP 
        3_CD production_NN [_NN 31_CD ]_NN ._. However_RB ,_, no_DT
        evidence_NN has_VBZ been_VBN presented_VBN for_IN a_DT direct_JJ interaction_NN
        between_IN β-arrestin_JJ and_CC the_DT GnRH_NNP receptor_NN ._.
        With_IN respect_NN to_TO the_DT G_NNP protein_NN as_IN a_DT locus_JJ for_IN modulation_NN
        of_IN GnRH_NNP receptor_NN signaling_VBG ,_, we_PRP reported_VBD earlier_RBR that_IN
        experimental_JJ expression_NN of_IN RGS_NNP 3_CD but_CC not_RB RGS_NNP 1_CD ,_, 2_CD ,_, or_CC 4_CD in_IN
        GnRH_NNP receptor_NN expressing_VBG COS-_NNP 1_CD cells_NNS suppressed_VBD
        GnRH-stimulated_NNP IP_NNP 
        3_CD production_NN [_NN 9_CD ]_NN ._. In_IN the_DT current_JJ
        report_NN ,_, we_PRP present_JJ evidence_NN strengthening_VBG the_DT hypothesis_NNS of_IN
        a_DT regulatory_JJ role_NN for_IN RGS_NNP 3_CD in_IN GnRH_NNP receptor_NN signaling_VBG :_:
        adenovirus-mediated_JJ expression_NN of_IN RGS_NNP 3_CD in_IN normal_JJ pituitary_JJ
        gonadotropes_NNS profoundly_RB inhibited_VBD GnRH-stimulated_NNP LH_NNP
        secretion_NN and_CC 3_CD H-_NNP inositol_NN phosphate_NN accumulation_NN ._. Arguing_VBG
        for_IN the_DT specificity_NN of_IN this_DT effect_NN is_VBZ the_DT stimulation_NN of_IN LH_NNP
        secretion_NN by_IN a_DT calcium_NN ionophore_NN and_CC the_DT failure_NN of_IN LH_NNP
        stores_NNS and_CC GnRH-receptor_NNP binding_JJ to_TO be_VB affected_VBN by_IN RGS_NNP 3_CD ._.
        Moreover_RB ,_, our_PRP$ finding_VBG that_IN GnRH-stimulated_NNP IP_NNP 
        3_CD production_NN was_VBD inhibited_VBD supports_VBZ the_DT
        locus_JJ of_IN the_DT RGS_NNP 3_CD effect_NN as_IN residing_VBG at_IN phospholipase_NN C_NNP or_CC
        earlier_RBR in_IN the_DT transduction_NN pathway_NN ,_, most_RBS likely_JJ at_IN the_DT Gα_NNP
        protein_NN because_IN of_IN our_PRP$ studies_NNS both_DT earlier_JJR [_NN 9_CD ]_NN and_CC here_RB
        showing_VBG that_IN RGS_NNP 3_CD binds_NNS Gqα_NNP 
        in_IN vitro_NN ._. Finally_RB ,_, the_DT stronger_JJR
        inhibitory_NN effect_NN of_IN RGS_NNP 3_CD T_NN than_IN RGS_NNP 3_CD on_IN COS_NNP cell_NN function_NN
        was_VBD presumed_VBN to_TO be_VB true_JJ also_RB for_IN gonadotrope_NN function_NN and_CC
        therefore_RB was_VBD not_RB tested_VBN here_RB ._.
        The_DT determination_NN of_IN RGS_NNP specificity_NN for_IN receptor-_NN G_NNP
        protein_NN pairs_NNS are_VBP currently_RB unknown_JJ ;_: i_NNP ._. e_SYM ._. ,_, we_PRP and_CC others_NNS
        have_VBP found_VBN that_IN several_JJ RGSs_NNP interact_NN with_IN Gqα_NNP but_CC only_RB
        one_CD ,_, RGS_NNP 3_CD ,_, has_VBZ potent_JJ inhibitory_NN activity_NN on_IN GnRH_NNP receptor_NN
        signaling_VBG ._. For_IN instance_NN ,_, RGS_NNP 4_CD and_CC RGS-GAIP_NNP [_NN 11_CD ]_NN ,_, RGS_NNP 3_CD [_NN
        9_CD ]_NN ,_, RGS_NNP 2_CD [_NN 46_CD ]_NN ,_, and_CC RGS_NNP 7_CD (_( our_PRP$ unpublished_JJ findings_NNS )_) all_DT
        bind_NN Gqα_NNP ,_, the_DT established_VBN G_NNP protein_NN that_IN transduces_NNS GnRH_NNP
        receptor_NN signaling_VBG [_NN 38_CD ]_NN ._. Nevertheless_RB ,_, RGS_NNP 2_CD and_CC 4_CD [_NN 9_CD ]_NN
        ,_, and_CC RGS-GAIP_NNP and_CC RGS_NNP 7_CD (_( our_PRP$ unpublished_JJ data_NNS )_) are_VBP weak_JJ or_CC
        null_NN inhibitors_NNS of_IN GnRH_NNP receptor_NN signaling_VBG ._. A_DT recent_JJ report_NN
        seems_VBZ to_TO have_VB clarified_VBN this_DT issue_NN :_: RGS_NNP 4_CD must_MD bind_NN not_RB only_RB
        Gqα_NNP but_CC also_RB selected_VBN Gq-coupled_NNP receptors_NNS before_IN it_PRP can_MD
        inhibit_VB receptor_NN signaling_VBG [_NN 47_CD 48_CD ]_NN ._. Based_VBN on_IN this_DT
        finding_NN ,_, we_PRP propose_VBP that_IN RGS_NNP 3_CD 's_POS binding_VBG to_TO the_DT GnRH_NNP
        receptor_NN as_RB well_RB as_IN to_TO Gqα_NNP accounts_NNS for_IN its_PRP$ specific_JJ
        inhibiting_VBG of_IN GnRH_NNP receptor_NN signaling_VBG ._.
      
      
        Conclusions_NNP
        The_DT results_NNS of_IN the_DT current_JJ investigation_NN as_RB well_RB as_IN
        those_DT presented_VBN earlier_JJR [_NN 31_CD ]_NN nominate_VB two_CD molecular_JJ
        mechanisms_NNS as_IN playing_VBG roles_NNS in_IN setting_VBG the_DT responsiveness_NNS
        level_NN of_IN GnRH_NNP receptor_NN signaling_VBG ;_: i_NNP ._. e_SYM ._. ,_, the_DT RGS_NNP 3_CD system_NN
        acts_NNS at_IN the_DT G_NNP protein_NN transducing_VBG step_NN and_CC the_DT GRK_NNP /_NN β_NN
        arrestin_NN system_NN acts_NNS at_IN the_DT level_NN of_IN the_DT receptor_NN ._. Future_JJ
        studies_NNS must_MD address_VB whether_IN both_DT ,_, neither_DT ,_, or_CC only_RB one_CD of_IN
        these_DT mechanisms_NNS are_VBP physiologically_RB relevant_JJ ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          cDNA_NN transfection_NN of_IN COS-_NNP 1_CD cells_NNS and_CC measurement_NN of_IN
          IP_NNP 3_CD production_NN
          cDNA_NN representing_VBG the_DT rat_NN GnRH_NNP receptor_NN was_VBD cloned_VBN
          into_IN pcDNA_NN 3_CD as_IN described_VBN and_CC validated_JJ previously_RB [_NN 22_CD 23_CD
          ]_NN ._. cDNAs_NNS representing_VBG RGS_NNP 3_CD and_CC RGS_NNP 3_CD T_NN (_( RGS_NNP 3_CD amino_JJ acids_NNS
          314_CD -_: 519_CD )_) were_VBD cloned_VBN into_IN the_DT eukaryotic_JJ expression_NN
          vector_NN ,_, rcCMV_NN ,_, as_IN described_VBN [_NN 24_CD ]_NN ._. COS-_NNP 1_CD cells_NNS cultured_JJ
          as_IN detailed_JJ before_IN [_NN 23_CD ]_NN were_VBD co-transfected_JJ with_IN GnRH_NNP
          receptor_NN cDNA_NN and_CC RGS_NNP 3_CD or_CC RGS_NNP 3_CD T_NN cDNA_NN using_VBG Lipofectamine_NNP
          (_( Life_NNP Technologies_NNPS ,_, Gaithersburg_NNP ,_, MD_NNP )_) [_NN 23_CD ]_NN ,_, and_CC 72_CD h_NN
          later_RB ,_, treated_VBN with_IN 10_CD -_: 7_CD M_NNP GnRH-A_NNP for_IN 0_CD ,_, 10_CD ,_, 20_CD ,_, or_CC 30_CD
          sec_NN before_IN being_VBG collected_VBN for_IN IP_NNP 
          3_CD measurements_NNS [_NN 22_CD 23_CD ]_NN ._.
          IP_NNP 
          3_CD measurements_NNS were_VBD performed_VBN on_IN COS-_NNP 1_CD
          cell_NN cytosolic_JJ preparations_NNS using_VBG a_DT radioreceptor_NN assay_NN
          in_IN which_WDT IP_NNP 
          3_CD and_CC 3_CD H-IP_NNP 
          3_CD compete_VB for_IN binding_JJ to_TO IP_NNP 
          3_CD receptors_NNS prepared_VBN from_IN calf_NN
          cerebellum_NN membranes_NNS [_NN 22_CD 23_CD ]_NN ._.
        
        
          RGS_NNP 3_CD binding_JJ of_IN Gα-proteins_NNP in_IN vitro_NN
          RGS_NNP 3_CD protein_NN fused_JJ to_TO glutathione-_NN S-_NNP transferase_NN
          (_( RSG_NNP 3_CD -_: GST_NNP fusion_NN protein_NN )_) was_VBD produced_VBN in_IN the_DT pGEX-_NN 5_CD x-_NN 1_CD
          system_NN of_IN Pharmacia_NNP as_IN detailed_JJ previously_RB [_NN 9_CD ]_NN ._.
          35_CD S-M_NNP et_CC labeled_VBN Gα-proteins_NNP were_VBD prepared_VBN 
          in_IN vitro_NN using_VBG a_DT
          transcription_NN /_NN translation_NN protocol_NN [_NN 9_CD ]_NN ._. cDNAs_NNS for_IN Gqα_NNP
          [_NN 25_CD ]_NN and_CC Gzα_NNP [_NN 26_CD ]_NN were_VBD obtained_VBN from_IN M_NNP ._. I_PRP ._. Simon_NNP ;_: for_IN
          Gsα_NNP (_( ref_NN ._. No_UH ._. 63315_CD )_) and_CC Gi_NNP 2_CD α_NN (_( ref_NN ._. No_UH ._. 63311_CD )_) were_VBD
          obtained_VBN from_IN the_DT American_NNP Type_NNP Culture_NNP Collection_NNP
          (_( ATCC_NNP )_) ;_: for_IN Gαo_NNP [_NN 27_CD ]_NN was_VBD obtained_VBN from_IN Eva_NNP G_NNP ._. Neer_NNP ;_: for_IN
          Gi_NNP 1_CD α_NN ,_, [_NN 28_CD ]_NN from_IN G_NNP ._. R_NN ._. Post_NNP ;_: and_CC ,_, for_IN Gi_NNP 3_CD α_NN [_NN 29_CD ]_NN from_IN
          M_NNP ._. G_NNP ._. Farquhar_NNP ._. Binding_NNP studies_NNS of_IN recombinant_JJ RGS_NNP 3_CD -_: GST_NNP
          fusion_NN protein_NN to_TO 35_CD S-M_NNP et-_NN Gα-proteins_NNP were_VBD performed_VBN as_IN
          detailed_JJ [_NN 9_CD ]_NN ._. Glutathione-coupled_NNP beads_NNS were_VBD used_VBN to_TO
          select_VB 35_CD S-G_NNP α_NN proteins_NNS bound_VBN to_TO RGS_NNP 3_CD -_: GST_NNP ,_, and_CC were_VBD then_RB
          eluted_JJ for_IN separation_NN by_IN SDS_NNP /_NN PAGE_NNP [_NN 9_CD ]_NN ._. The_DT amount_NN and_CC
          molecular_JJ size_NN of_IN 35_CD S-G_NNP α_NN protein_NN were_VBD determined_VBN using_VBG a_DT
          Phosphor_NNP imaging_NN device_NN (_( Molecular_NNP Dynamics_NNP )_) ._.
        
        
          Preparation_NNP of_IN Adeno-_NNP RGS_NNP 3_CD
          Recombinant_NNP adenovirus_JJ containing_VBG RGS_NNP 3_CD cDNA_NN was_VBD
          prepared_VBN using_VBG procedures_NNS previously_RB described_VBD in_IN detail_NN
          by_IN Becker_NNP 
          et_CC al_NN ._. [_NN 30_CD ]_NN and_CC by_IN us_PRP [_NN 31_CD ]_NN ._.
          Human_NNP RGS_NNP 3_CD cDNA_NN [_NN 24_CD ]_NN was_VBD restricted_VBN from_IN the_DT pRC_NN /_NN CMV_NNP
          vector_NN with_IN EcoRI_NNP ,_, and_CC then_RB subcloned_JJ into_IN the_DT
          corresponding_JJ site_NN of_IN the_DT pACCMVpLpa_NN plasmid_NN ._. The_DT proper_JJ
          orientation_NN of_IN the_DT RGS_NNP 3_CD cDNA_NN was_VBD confirmed_VBN by_IN nucleotide_NN
          sequencing_VBG ._. The_DT procedure_NN for_IN preparation_NN of_IN the_DT
          adenovirus_JJ was_VBD co-transfection_JJ of_IN a_DT human_JJ embryonic_JJ
          kidney_NN cell_NN line_NN (_( HEK_NNP 293_CD )_) with_IN the_DT pACCMVpLpa_NN plasmid_NN
          and_CC another_DT plasmid_NN (_( pJM_NN 17_CD )_) containing_VBG most_JJS of_IN the_DT viral_JJ
          genome_NN [_NN 30_CD ]_NN ._. A_DT relatively_RB rare_JJ recombination_NN of_IN the_DT
          two_CD plasmids_NNS occurs_VBZ in_IN the_DT HEK_NNP 293_CD cells_NNS that_IN
          reconstitutes_NNS the_DT adenoviral_NN genome_NN ._. The_DT recombination_NN
          event_NN reconstituting_VBG adeno-_NN RGS_NNP 3_CD was_VBD confirmed_VBN using_VBG PCR_NNP
          analysis_NN to_TO detect_VB the_DT presence_NN of_IN RGS_NNP 3_CD cDNA_NN ._. Next_JJ ,_,
          adeno-_NN RGS_NNP 3_CD was_VBD isolated_VBN by_IN clonal_NN selection_NN in_IN HEK_NNP 293_CD
          cells_NNS followed_VBN by_IN a_DT second_JJ PCR_NNP to_TO confirm_VB the_DT presence_NN of_IN
          RGS_NNP 3_CD cDNA_NN ._. Finally_RB ,_, large-scale_JJ amplification_NN and_CC
          titering_VBG of_IN adeno-_NN RGS_NNP 3_CD was_VBD performed_VBN in_IN HEK_NNP 293_CD cells_NNS ._.
          This_DT virus_NN preparation_NN was_VBD used_VBN for_IN infection_NN of_IN rat_NN
          pituitary_JJ cells_NNS [_NN 31_CD ]_NN ._.
        
        
          Culture_NNP and_CC infection_NN of_IN rat_NN pituitary_JJ cells_NNS
          Anterior_NNP pituitary_JJ glands_NNS were_VBD obtained_VBN from_IN female_JJ
          Charles_NNP River_NNP CD_NNP rats_NNS that_WDT were_VBD maintained_VBN in_IN accordance_NN
          with_IN the_DT NIH_NNP Guide_NNP for_IN the_DT Care_NNP and_CC Use_NN of_IN Laboratory_NNP
          Animals_NNPS using_VBG an_DT experimental_JJ protocol_NN that_WDT had_VBD been_VBN
          approved_VBN by_IN the_DT Institutional_NNP Animal_NNP Care_NNP and_CC Use_NNP
          Committee_NNP ._. The_DT pituitaries_NNS were_VBD dispersed_VBD with_IN trypsin_NN as_IN
          described_VBN before_IN [_NN 32_CD ]_NN ._. The_DT mono-dispersed_JJ cells_NNS were_VBD
          plated_JJ into_IN poly-_NN L-_NNP lysine_NN coated_JJ 60_CD mm_NN plastic_NN Petri_NNP
          dishes_NNS in_IN DMEM_NNP /_NN 10_CD %_NN gelding_VBG horse_NN serum_NN containing_VBG 10_CD -_: 9_CD M_NNP
          estradiol_NN to_TO optimize_NN the_DT GnRH-responsiveness_NNP of_IN the_DT
          gonadotropes_NNS [_NN 33_CD ]_NN ,_, and_CC incubated_JJ overnight_JJ at_IN 37_CD °_NN C_NNP in_IN
          8_CD %_NN CO_NNP 
          2_CD -_: 92_CD %_NN air_NN ._.
          Pituitary_NNP cells_NNS were_VBD infected_JJ using_VBG a_DT volume_NN of_IN
          adeno-_NN RGS_NNP 3_CD or_CC adeno-β_JJ galactosidase_NN necessary_JJ to_TO achieve_VB
          the_DT chosen_VBN multiplicity_NN of_IN infection_NN (_( M_NNP ._. O_NNP ._. I_PRP ._. )_) diluted_VBN to_TO
          0_CD ._. 3_CD ml_NN ;_: this_DT was_VBD further_RBR diluted_VBN with_IN 1_CD ._. 2_CD ml_NN of_IN TS_NNP buffer_NN
          (_( 8_CD ._. 0_CD gm_NN /_NN L_NNP NaCI_NNP ,_, 380_CD mg_NN /_NN L_NNP KCl_NNP ,_, 100_CD mg_NN /_NN L_NNP Na_NNP 
          2_CD HPO_NNP 
          4_CD ,_, 3_CD ._. 0_CD gm_NN /_NN L_NNP Tris_NNP HCI_NNP ,_, 200_CD mg_NN /_NN L_NNP CaCl_NNP 
          2_CD ·_NN 2_CD H_NNP 
          2_CD O_NNP ,_, 100_CD mg_NN /_NN L_NNP MgCl_NNP 
          2_CD ·_NN 6_CD H_NNP 
          2_CD O_NNP ;_: pH_NN 7_CD ._. 4_LS )_) ._. The_DT pituitary_JJ cell_NN
          culture_NN medium_NN was_VBD aspirated_JJ and_CC replaced_VBN with_IN the_DT virus_NN
          solution_NN ,_, and_CC the_DT cells_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP in_IN a_DT CO_NNP 
          2_CD incubator_NN for_IN approximately_RB 72_CD
          h_NN ._.
          Next_JJ ,_, the_DT cells_NNS were_VBD collected_VBN by_IN trypsinization_NN and_CC
          counted_VBN using_VBG a_DT hemocytometer_NN ;_: then_RB ,_, they_PRP were_VBD checked_VBN
          for_IN viability_NN using_VBG trypan_NN blue_JJ [_NN 31_CD ]_NN ._. The_DT cells_NNS were_VBD
          replated_JJ for_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP in_IN DMEM_NNP -_: 0_CD ._. 1_LS %_NN bovine_JJ serum_NN
          albumin_NN (_( BSA_NNP )_) and_CC subjected_VBN to_TO x-gal_JJ staining_VBG for_IN
          determination_NN of_IN the_DT fraction_NN of_IN cells_NNS infected_VBN by_IN the_DT
          virus_NN [_NN 31_CD ]_NN ,_, or_CC to_TO stimulation_NN by_IN GnRH-A_NNP for_IN
          measurement_NN of_IN LH_NNP release_NN ._.
        
        
          GnRH-stimulated_NNP LH_NNP secretion_NN
          Pituitary_NNP cells_NNS that_WDT had_VBD been_VBN re-trypsinized_JJ 72_CD h_NN
          after_IN infection_NN and_CC then_RB replated_JJ (_( 100_CD ,_, 000_CD cells_NNS /_NN well_RB in_IN
          a_DT 24_CD -_: well_RB poly-_NN L-_NNP lysine_NN coated_JJ plate_NN )_) for_IN a_DT 2_CD h_NN
          preincubation_NN were_VBD subsequently_RB treated_VBN with_IN a_DT GnRH_NNP
          agonist_NN (_( 1_CD ml_NN of_IN 10_CD -_: 7_CD M_NNP D-A_NNP la_FW 6_CD -_: des_NNP Gly_NNP 10_CD -_: GnRH_NNP
          ethylamide_NN ;_: GnRH-A_NNP ,_, Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) or_CC a_DT calcium_NN
          ionophore_NN (_( A_DT 23187_CD ,_, Sigma_NNP )_) for_IN 3_CD h_NN as_IN described_VBN by_IN Conn_NNP 
          et_CC al_NN ._. [_NN 34_CD ]_NN ._. The_DT medium_NN was_VBD
          removed_VBN and_CC centrifuged_JJ at_IN 200_CD ×_NN g_SYM for_IN 10_CD min_NN to_TO pellet_NN
          any_DT detached_VBN cells_NNS ._. The_DT supernatant_NN solution_NN was_VBD either_CC
          used_VBN immediately_RB or_CC stored_VBD at_IN -_: 20_CD °_NN C_NNP prior_RB to_TO RIA_NNP ._.
          LH_NNP RIAs_NNP were_VBD performed_VBN using_VBG reagents_NNS and_CC instructions_NNS
          provided_VBN by_IN Dr_NNP ._. A_DT ._. F_NN ._. Parlow_NNP on_IN behalf_NN of_IN the_DT National_NNP
          Hormone_NNP and_CC Pituitary_NNP Program_NNP ,_, National_NNP Institute_NNP of_IN
          Diabetes_NNP and_CC Digestive_NNP and_CC Kidney_NNP Diseases_NNP ,_, NIH_NNP ._. Rat_NNP LH_NNP
          (_( NIDDK-rLH-l-_NNP 9_CD )_) was_VBD radioiodinated_JJ ,_, the_DT LH_NNP antiserum_NN
          (_( NIDDK-anti-rLH-S-_NNP 11_CD )_) was_VBD prepared_VBN in_IN rabbits_NNS ,_, and_CC the_DT
          reference_NN standard_NN was_VBD NIDDK-rLH-RP_NNP 3_CD ._. The_DT mean_NN EC_NNP 
          50_CD of_IN the_DT standard_JJ curves_NNS (_( n_NN =_SYM 10_CD )_) was_VBD
          0_CD ._. 59_CD ng_NN with_IN a_DT coefficient_NN of_IN variation_NN of_IN 4_CD ._. 4_CD %_NN ._.
        
        
          GNRH-stimulated_NNP 3_CD H-_NNP inositol_NN phosphate_NN accumulation_NN
          in_IN pituitary_JJ cells_NNS
          Total_JJ [_NN 3_CD H_NNP ]_NN inositol_NN phosphate_NN accumulation_NN was_VBD
          determined_VBN in_IN [_NN 3_CD H_NNP ]_NN myoinositol-labeled_JJ pituitary_JJ cells_NNS
          as_IN described_VBN earlier_JJR [_NN 22_CD ]_NN ._. At_IN 48_CD h_NN after_IN infection_NN of_IN
          the_DT pituitary_JJ cells_NNS ,_, the_DT incubation_NN medium_NN was_VBD removed_VBN
          and_CC replaced_VBN with_IN a_DT balanced_JJ salt_NN solution_NN (_( 10_CD mM_NN Hepes_NNP ,_,
          pH_NN 7_CD ._. 4_LS ,_, 135_CD mM_NN NaCI_NNP ,_, 4_CD ._. 5_CD mM_NN KCL_NNP ,_, 1_CD ._. 5_CD mM_NN CaCl_NNP 
          2_CD ,_, 0_CD ._. 5_CD mM_NN MgCL_NNP 
          2_CD ,_, 1_CD ._. 0_CD mM_NN NaH_NNP 
          2_CD PO_NNP 4_CD ,_, 5_CD ._. 6_CD mM_NN glucose_NN ,_, 0_CD ._. 3_CD %_NN BSA_NNP ,_, and_CC
          10_CD -_: 9_CD M_NNP estradiol_NN )_) containing_VBG 5_CD μCi_NN of_IN [_NN
          3_CD H_NNP ]_NN -_: myoinositol_NN /_NN ml_NN of_IN medium_NN ._. After_IN a_DT further_JJ 24_CD h_NN ,_, the_DT
          pituitary_JJ cells_NNS were_VBD recovered_VBN by_IN trypinization_NN ,_, counted_VBN ,_,
          and_CC replated_JJ in_IN balanced_JJ salt_NN solution_NN (_( 400_CD ,_, 000_CD -_: 500_CD ,_, 000_CD
          cells_NNS /_NN well_RB in_IN a_DT 24_CD -_: well_RB plate_NN )_) for_IN a_DT 2_CD h_NN preincubation_NN ._.
          Then_RB ,_, the_DT cells_NNS were_VBD stimulated_VBN with_IN GnRH-A_NNP (_( 10_CD -_: 7_CD M_NNP for_IN
          one_CD hr_NN )_) in_IN the_DT presence_NN of_IN 5_CD mM_NN LiCI_NNP ._. [_NN 3_CD H_NNP ]_NN -_: inositol_NN
          phosphate_NN accumulation_NN in_IN the_DT cells_NNS was_VBD then_RB measured_VBN
          using_VBG ion_NN exchange_NN chromatography_NN followed_VBN by_IN liquid_JJ
          scintillation_NN spectroscopy_NN [_NN 22_CD ]_NN ._.
        
        
          Immunoblots_NNP for_IN RGS_NNP 3_CD
          An_DT antibody_NN to_TO hexa-histidine-tagged_JJ human_JJ RGS_NNP 3_CD T_NN was_VBD
          prepared_VBN in_IN chickens_NNS ._. RGS_NNP 3_CD T_NN [_NN 24_CD ]_NN is_VBZ the_DT carboxy_NN
          terminal_NN 206_CD amino_JJ acids_NNS (_( a_DT ._. a_DT ._. 314_CD -_: 519_CD )_) of_IN RGS_NNP 3_CD and_CC is_VBZ
          represented_VBN by_IN nt_RB 1227_CD -_: 1847_CD of_IN RGS_NNP 3_CD cDNA_NN (_( Genbank_NNP
          Accession_NNP #_# U_NNP 27655_CD )_) ._. To_TO prepare_VB hexa-histidine_JJ amino_JJ
          terminally-tagged_JJ RGS_NNP 3_CD T_NN ,_, we_PRP modified_VBN RGS_NNP 3_CD T_NN cDNA_NN [_NN 24_CD ]_NN
          using_VBG PCR_NNP with_IN primers_NNS containing_VBG restriction_NN sites_NNS (_( the_DT
          5_CD '_POS primer_NN incorporated_VBD a_DT Bam_UH HI_NNP site_NN ,_, whereas_IN the_DT 3_CD '_POS
          primer_NN bore_VBD an_DT Nde_NNP 1_CD site_NN )_) ._. The_DT PCR_NNP product_NN was_VBD then_RB
          cloned_VBN into_IN the_DT pET_NN 15_CD b_SYM vector_NN which_WDT carries_VBZ an_DT N-_NNP terminal_NN
          Histag_NNP sequence_NN followed_VBN by_IN BamH_NNP 1_CD and_CC Nde_NNP 1_CD cloning_VBG sites_NNS
          (_( Novagen_NNP Inc_NNP ._. ,_, Madison_NNP ,_, WI_NNP )_) ._. The_DT resulting_VBG plasmid_NN DNA_NNP
          was_VBD nucleotide-sequenced_JJ to_TO confirm_VB the_DT presence_NN of_IN RGS_NNP 3_CD T_NN
          cDNA_NN ._. The_DT cDNA_NN was_VBD then_RB used_VBN to_TO transform_VB 
          E_NNP ._. coli_NNS of_IN the_DT BL_NNP 21_CD (_( DE_NNP 3_LS )_) strain_NN ._.
          Protein_NNP induction_NN was_VBD performed_VBN using_VBG
          isopropyl-β-_JJ D-_NNP thiogalactopyranoside_NN (_( IPTG_NNP )_) as_IN described_VBN
          by_IN Novagen_NNP Inc_NNP ._. Inclusion_NNP bodies_NNS containing_VBG the_DT protein_NN
          were_VBD prepared_VBN and_CC then_RB solubized_JJ in_IN 6_CD M_NNP guanidine_NN ._. The_DT
          Histag_NNP RGS_NNP 3_CD T_NN protein_NN was_VBD purified_JJ on_IN a_DT Ni_NNP 2_CD +_NN resin_NN using_VBG a_DT
          Pharmacia_NNP Hi-_NNP Trap_NNP 1_CD ml_NN Chelating_NNP Column_NNP (_( Pharmacia_NNP
          Biotech_NNP ,_, Piscataway_NNP ,_, NJ_NNP )_) ._.
          Antibodies_NNP to_TO Histag_NNP RGS_NNP 3_CD T_NN protein_NN were_VBD prepared_VBN in_IN
          chickens_NNS (_( Aves_NNP Labs_NNPS ,_, Inc_NNP ._. ,_, Tigard_NNP ,_, OR_NNP )_) ._. A_DT chicken_NN was_VBD
          injected_VBN with_IN 145_CD μg_NN of_IN RGS_NNP 3_CD T_NN into_IN the_DT breast_NN muscle_NN on_IN
          four_CD separate_JJ occasions_NNS ;_: the_DT first_JJ injection_NN was_VBD in_IN
          complete_JJ Freund_NNP 's_POS adjuvant_NN ,_, whereas_IN injections_NNS 2_CD -_: 4_CD were_VBD
          made_VBN in_IN a_DT 1_CD :_: 1_CD dilution_NN of_IN complete_JJ and_CC incomplete_JJ
          Freund_NNP 's_POS adjuvant_NN ._. One_CD week_NN after_IN the_DT last_JJ injection_NN ,_, 6_CD
          immune_JJ eggs_NNS were_VBD collected_VBN ,_, and_CC the_DT IgY_NNP fraction_NN purified_JJ
          from_IN the_DT 6_CD eggs_NNS as_RB well_RB as_IN from_IN 3_CD pre-immune_JJ eggs_NNS
          collected_VBN from_IN the_DT same_JJ hen_NN ._.
          Immunoblots_NNP for_IN RGS_NNP 3_CD expression_NN in_IN pituitary_JJ cells_NNS
          were_VBD performed_VBN as_IN described_VBN previously_RB by_IN us_PRP [_NN 22_CD 23_CD ]_NN ._.
          In_IN brief_JJ ,_, rat_NN pituitary_JJ cells_NNS at_IN 72_CD h_NN after_IN adeno-_NN RGS_NNP 3_CD
          infection_NN (_( 5_CD M_NNP ._. O_NNP ._. I_PRP ._. )_) were_VBD collected_VBN by_IN trypsinization_NN ,_,
          homogenized_JJ ,_, and_CC a_DT protein_NN determination_NN made_VBN ._. Fifty_NNP μg_NN
          protein_NN samples_NNS were_VBD heated_JJ in_IN SDS-PAGE_NNP sample_NN buffer_NN
          containing_VBG β-mercaptoethanol_JJ and_CC then_RB electrophoresed_JJ on_IN
          a_DT 10_CD %_NN SDS-polyacrylamide_NNP gel_NN ._. Separated_NNP proteins_NNS were_VBD
          electroblotted_JJ onto_IN nylon_NN membranes_NNS (_( Millipore_NNP Corp_NNP ._. ,_,
          Bedford_NNP ,_, MA_NNP )_) which_WDT were_VBD then_RB incubated_JJ for_IN 2_CD h_NN in_IN a_DT
          blocking_VBG solution_NN containing_VBG 5_CD %_NN non-fat_JJ dry_JJ milk_NN in_IN
          phosphate_NN buffered_JJ saline_NN containing_VBG 0_CD ._. 02_CD %_NN Tween-_NNP 20_CD ._. The_DT
          primary_JJ antibody_NN (_( chicken_NN IgY_NNP ,_, 62_CD ._. 5_LS μg_NN /_NN ml_NN )_) was_VBD diluted_VBN in_IN
          blocking_VBG solution_NN and_CC incubated_JJ overnight_JJ at_IN 4_CD °_NN C_NNP with_IN the_DT
          nylon_NN membrane_NN ._. Blots_NNP were_VBD then_RB incubated_JJ for_IN 2_CD h_NN at_IN room_NN
          temperature_NN in_IN alkaline_NN phosphatase-conjugated_JJ goat_NN
          anti-chicken_JJ IgY_NNP (_( 0_CD ._. 1_LS μg_NN /_NN ml_NN diluted_VBN in_IN blocking_VBG solution_NN ;_:
          Aves_NNP Labs_NNPS ,_, Tigard_NNP ,_, OR_NNP )_) ._. Color_NN development_NN was_VBD achieved_VBN by_IN
          incubating_VBG the_DT membrane_NN in_IN substrate_NN
          [_NN (_( 5_CD -_: bromo-_NN 4_CD -_: chloro-_NN 3_CD -_: indolyl_NN
          phosphate-nitrobluetetra-zolium_JJ chloride_NN )_)
          (_( BCIP-NBT_NNP )_) ]_NN ._.
        
        
          Assay_NNP of_IN LH_NNP contents_NNS in_IN pituitary_JJ cells_NNS
          For_IN LH_NNP RIA_NNP measurements_NNS of_IN cell_NN contents_NNS ,_, 1_CD ×_NN 10_CD
          5_CD anterior_NN pituitary_JJ cells_NNS infected_JJ ,_, or_CC not_RB ,_, 72_CD h_NN
          previously_RB with_IN adeno-_NN RGS_NNP 3_CD or_CC adeno-βgal_JJ were_VBD trypsinized_JJ
          and_CC plated_JJ for_IN 2_CD h_NN ._. LH_NNP was_VBD extracted_VBN from_IN the_DT cells_NNS [_NN 36_CD
          ]_NN by_IN removing_VBG and_CC discarding_VBG the_DT medium_NN and_CC adding_VBG 1_CD ml_NN
          extraction_NN buffer_NN (_( 150_CD mM_NN NaCI_NNP ,_, 50_CD mM_NN Tris_NNP ,_, 5_CD mM_NN EDTA_NNP ,_,
          and_CC 1_CD mM_NN bacitracin_NN ,_, pH_NN 7_CD ._. 4_LS )_) followed_VBN by_IN freeze-thawing_JJ
          twice_RB ._. After_IN centrifugation_NN ,_, the_DT supernatant_NN was_VBD removed_VBN
          and_CC subjected_VBN to_TO LH_NNP RIA_NNP as_IN described_VBN above_IN ._.
        
        
          Measurements_NNP of_IN GnRH_NNP receptors_NNS by_IN receptor_NN
          radioassay_NN (_( RRA_NNP )_)
          About_IN 3_CD ×_NN 10_CD 6_CD pituitary_JJ cells_NNS infected_JJ ,_, or_CC not_RB ,_, 72_CD h_NN
          previously_RB with_IN adeno-βgal_JJ or_CC adeno-_NN RGS_NNP 3_CD were_VBD
          trypsinized_JJ ,_, and_CC cell_NN membranes_NNS containing_VBG the_DT GnRH_NNP
          receptors_NNS were_VBD prepared_VBN by_IN placing_VBG the_DT cells_NNS in_IN a_DT Dounce_NNP
          homogenizer_NN (_( Kontes_NNP Co_NNP ._. ,_, Vineland_NNP ,_, NJ_NNP )_) and_CC disrupting_VBG
          them_PRP with_IN 30_CD strokes_NNS of_IN the_DT pestle_NN ._. The_DT cell_NN membranes_NNS
          were_VBD pelleted_JJ by_IN centrifugation_NN at_IN 26_CD ,_, 000_CD ×_NN 
          g_SYM and_CC then_RB resuspended_JJ in_IN 10_CD mM_NN
          Tris_NNP buffer_NN ._. The_DT GnRH_NNP RRA_NNP on_IN the_DT membranes_NNS was_VBD performed_VBN
          as_IN described_VBN previously_RB [_NN 22_CD 23_CD ]_NN ._. Cell_NNP membranes_NNS and_CC 1_CD
          ×_NN 10_CD 5_CD cpm_NN [_NN 125_CD I_PRP ]_NN GnRH-A_NNP were_VBD incubated_JJ at_IN 0_CD °_NN C_NNP for_IN 90_CD min_NN ._.
          Nonspecific_NNP binding_JJ was_VBD determined_VBN as_IN counts_VBZ per_IN min_NN
          bound_VBN in_IN the_DT presence_NN of_IN 10_CD -_: 6_CD M_NNP unlabeled_JJ GnRH-A_NNP ._. Bound_NNP
          and_CC free_JJ [_NN 125_CD I_PRP ]_NN GnRH-A_NNP were_VBD separated_VBN by_IN filtration_NN ._. The_DT
          filters_NNS were_VBD counted_VBN by_IN γ-scintillation_JJ spectrometry_NN ._.
        
        
          Data_NNP analysis_NN
          The_DT results_NNS are_VBP presented_VBN as_IN the_DT mean_JJ ±_NN SEM_NNP of_IN at_IN
          least_JJS three_CD independent_JJ experiments_NNS unless_IN indicated_VBD
          otherwise_RB ._. The_DT statistical_JJ tests_NNS were_VBD one-way_JJ or_CC two-way_JJ
          analyses_NNS of_IN variance_NN with_IN significant_JJ differences_NNS (_( p_NN <_NN
          0_CD ._. 05_CD )_) identified_VBN by_IN the_DT Student_NNP -_: Newman-_NNP Keuls_NNP method_NN ._.
          Statistical_NNP analysis_NN was_VBD performed_VBN using_VBG Sigma_NNP Stat_NNP
          Statistical_NNP Software_NNP for_IN Windows_NNP (_( Jandel_NNP Scientific_NNP ,_, San_NNP
          Rafael_NNP ,_, CA_NNP )_) ._.
        
      
    
  
